Work

Efficacy and Safety of Ruxolitinib for Treatment of Symptomatic Chronic Myelomonocytic Leukemia (CMML): Results of a Multicenter Phase II Clinical Trial

Year: 2022

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2022-170144

Authors: Eric Padron, Sara M Tinsley-Vance, Amy E. DeZern, Hetty E. Carraway, Marlise R. Luskin, Gail J. Roboz, Onyee Chan, Meagan Horton, Aaron T. Gerds, David A. Sallman, Andrew Kuykendall, David Steensma, Maria E Balasis, Jeffrey E. Lancet, Mikkael A. Sekeres, Rami S. Komrokji

Institutions: Moffitt Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Cleveland Clinic, Dana-Farber Cancer Institute, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill Cornell Medical Center, University of Miami, Sylvester Comprehensive Cancer Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310102731

FWCI: 1.087

Cites:

Cited by: 8

Related to: 10